Our approach to energy and emissions
Rising temperatures and more frequent extreme weather events as a result of climate change pose a threat to our earth’s ecosystems. At the same time, economic stability can be shaken by the associated damage to infrastructure, and increase insurance costs. At Fresenius Kabi, we want to fight against this trend and make our contribution to a healthy world through our commitment to climate protection.
Our energy management: How we implement our commitment to climate protection
Fresenius Kabi operates on the global stage with 50 production sites and more than 42,000 employees. Consequently, we have to observe a large volume of statutory framework conditions relating to the environment. Even beyond these, we are always looking for ways to minimize our impact on the climate. We also implement our management approaches in line with this trajectory.
Our focus topics for 2023
- Energy saving and efficiency
- Procurement and company-owned generation of renewable energy
- Reduction of CO2 emissions
Management systems with certification
Improving efficiency and avoiding unnecessary consumption – this is the focus of our energy management system. In 2023, the system was certified in accordance with the standard ISO 50001 at 30 sites. We want to expand the number of certified sites to 100% by the end of 2026.
ISO 50001, in % |
|
20222 |
|
20232 |
|
Goal 2026 |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market segment Healthcare products/Fresenius Kabi |
|
53 |
|
74 |
|
100% |
||||||||||||||||
|
||||||||||||||||||||||
Greenhouse gas emissions: Climate neutrality by 2040
The Fresenius Group has set a target of achieving climate neutrality in Scopes 1 and 2 by 2040. We plan to achieve this primarily by implementing reduction measures, and offsetting any remaining greenhouse gas emissions. The first step towards achieving this goal is to reduce all Scope 1 and Scope 2 emissions by 50% in absolute terms by 2030 (base year: 2020).
Fresenius Kabi intends to contribute to our Group target particularly by utilizing renewable energies and energy efficiency measures. In 2023, we were able to reduce our Scope 1 and Scope 2 emissions by 24% in comparison with the previous year.
in thousand t CO2 equivalents |
|
2023 |
|
2022 |
|
2021 |
|
2020 |
|---|---|---|---|---|---|---|---|---|
Fresenius Kabi |
|
324 |
|
425 |
|
416 |
|
396 |
Scope 1 |
|
168 |
|
169 |
|
172 |
|
160 |
Scope 2 |
|
155 |
|
256 |
|
243 |
|
237 |
In 2023, Fresenius carried out work on the systematic recording and evaluation of the Group-wide Scope 3 emissions in accordance with the Greenhouse Gas Protocol Scope 3 Accounting and Reporting Standard, and is publishing these statistics for the first time in this report. Fresenius Kabi will provide a more detailed report on its Scope 3 emissions for the first time in 2024.
Expansion of renewable energies
In 2023, Fresenius Kabi purchased electricity generated from renewable energies for seven of its production facilities. This switch to renewable/CO2 neutral energy at all our production sites is intended to bring about an annual reduction of 6% in our Scope 1 and Scope 2 emissions, and also contributed to our 2023 reduction target. Furthermore, we already operate photovoltaic systems at nine production facilities, and three additional installations were approved for operation in 2023. They will go live on the grid in 2024.
Solar energy for MedTech production
This form of power is an important pillar for greater sustainability: solar energy. In 2022, we started up three new power stations at our production facilities in Guangzhou (China), Haina (Dominican Republic) and San Germán (Puerto Rico). The combined output of these power plants generates around 5,600,000 KWh of energy each year for the production of MedTech products – as much electricity as about 2,000 average two-person households consume over the same period.